The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Review
Overview
abstract
BACKGROUND: Despite surgical resection, long-term survival of patients with resectable non-small cell lung cancer (NSCLC) remains poor. Adjuvant chemotherapy, the standard of care for locally advanced NSCLC, provides a marginal 5.4% benefit in survival. Immune checkpoint inhibitors (ICIs) have shown a significant survival benefit in some patients with advanced NSCLC and are being evaluated for perioperative use in resectable NSCLC. METHODS: We conducted a literature search using the PubMed online database to identify clinical trials of immunotherapy in resectable NSCLC and studies analyzing biomarkers and immune priming strategies. RESULTS: Building upon previous phase I and II trials, CheckMate 816, KEYNOTE-671, IMpower010, and PEARLS/KEYNOTE-091 have shown efficacy of neoadjuvant nivolumab, perioperative pembrolizumab, adjuvant atezolizumab and adjuvant pembrolizumab, respectively, with improvement of event-free/disease-free survival of 24-42%, leading to FDA approval of these drugs in the treatment of resectable NSCLC. Phase III trials CheckMate 77T, AEGEAN, and Neotorch have also recently reported the use of immunotherapy both before and after surgery with pathologic complete response rates of 17%-25%, significantly better than chemotherapy alone. Perioperative ICI therapy has comparable perioperative morbidity to chemotherapy alone and does not impair surgical outcomes. CONCLUSIONS: Perioperative immunotherapy, in combination with chemotherapy, is safe and improves outcomes in patients with resectable NSCLC. Questions regarding patient selection, the need for adjuvant ICI therapy after neoadjuvant chemoimmunotherapy, and the duration of perioperative immunotherapy remain to be answered by future trials.
